TrialFuture oncology (London, England)2024

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Tom Waddell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.